Please assess the completion status of the following clinical trial:

Trial Title: Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Long-term care facilities within 75 miles of one of the 121 cities that serve as CDC surveillance sites~Exclusion Criteria:~* Facilities that used high dose influenza vaccine in residents over age 65 in previous influenza season (2015-16)~* Facilities having fewer than 50 long-stay residents~* Hospital-based facilities~* Facilities with more than 20% of the population under age 65~* Facilities not submitting Minimum Data Set (MDS) data

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aTIV (Type: EXPERIMENTAL): NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
- TIV (Type: ACTIVE_COMPARATOR): NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents

Based on this trial design, predict the completion outcome and termination type (if applicable).